Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DNA Genotek Inc.

Division of OraSure Technologies Inc.
www.dnagenotek.com

Latest From NovaQuest

No Approval, No Pay: VCs Bet Large On Late-Stage Pharma Trials

Some of the biggest life science VCs are spending hundreds of millions of dollars to run the clinical trials of drugs owned by big drugmakers. But if the strategy works, they may have come up with a better way to diversify their portfolios in an era when long-term company-building isn’t paying off.

BioPharmaceutical Business Strategies

Quintiles IPO Points To Increased Pharma Productivity And Outsourcing

Slated for May 9, this offering for the largest CRO is expected to attract a wide range of investors, including health care specialists and growth-oriented generalists. The IPO filing shows how the biopharma industry is rebounding. But the CRO’s risk-sharing projects with pharma, which gained attention in recent years, don’t seem to be that productive.

Clinical Trials Business Strategies

No Approval, No Pay: VCs Bet Large On Late-Stage Pharma Trials

Some of the biggest names in life science venture capital – OrbiMed Advisors, Clarus Ventures, and Abingworth – are spending hundreds of millions of dollars to run the clinical trials of drugs owned by Pfizer and other big drugmakers. They’re taking on major clinical and regulatory risks for what might be less-than-stellar returns but if it works, these VCs may have come up with a better way to diversify their portfolios in an era when long-term company-building isn’t paying off.

BioPharmaceutical Asia Pacific

Australia Earnings Roundup: CSL, Acrux, Pharmaxis, Mesoblast (Part 1)

PharmAsia News combs through earnings reports to bring you highlights on Australian biotech firms. We start with CSL Ltd, Acrux, Pharmaxis and Mesoblast for the period ended Dec. 31, 2012.

BioPharmaceutical Australia
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Saliva-based Testing
  • Medical Devices
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • OraSure Technologies Inc.
  • Senior Management
  • Ian Curry, Pres. & CEO
    Patrick Walsh, CFO
    H. Chaim Birnboim, CSO
  • Contact Info
  • DNA Genotek Inc.
    Phone: (866) 813-6354
    2 Beaverbrook Rd.
    Kanata, K2K 1L1
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register